BR112023023425A2 - Compostos heterocíclicos substituídos - Google Patents
Compostos heterocíclicos substituídosInfo
- Publication number
- BR112023023425A2 BR112023023425A2 BR112023023425A BR112023023425A BR112023023425A2 BR 112023023425 A2 BR112023023425 A2 BR 112023023425A2 BR 112023023425 A BR112023023425 A BR 112023023425A BR 112023023425 A BR112023023425 A BR 112023023425A BR 112023023425 A2 BR112023023425 A2 BR 112023023425A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituted heterocyclic
- heterocyclic compounds
- compounds
- useful
- present
- Prior art date
Links
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000011234 negative regulation of signal transduction Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
compostos heterocíclicos substituídos. a presente invenção refere-se a compostos da fórmula (i) que segue ou um estereoisômero ou sal farmaceuticamente aceitável dos mesmos, em que todos os substituintes são como definidos na presente invenção, que são úteis na modulação de il-12, il-23 e/ou ifna, através da ação sobre tyk-2 para causar inibição de transdução de sinal. os compostos da invenção podem ser úteis para tratamento de doenças ou distúrbios neurodegenerativos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188498P | 2021-05-14 | 2021-05-14 | |
| US202263318149P | 2022-03-09 | 2022-03-09 | |
| PCT/US2022/029102 WO2022241171A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023425A2 true BR112023023425A2 (pt) | 2024-01-30 |
Family
ID=81927926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023425A BR112023023425A2 (pt) | 2021-05-14 | 2022-05-13 | Compostos heterocíclicos substituídos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11866414B2 (pt) |
| EP (1) | EP4337655A1 (pt) |
| JP (1) | JP2024518554A (pt) |
| KR (1) | KR20240008336A (pt) |
| AU (1) | AU2022271794A1 (pt) |
| BR (1) | BR112023023425A2 (pt) |
| CA (1) | CA3217332A1 (pt) |
| CL (1) | CL2023003308A1 (pt) |
| CO (1) | CO2023015226A2 (pt) |
| IL (1) | IL308421A (pt) |
| TW (1) | TW202311247A (pt) |
| WO (1) | WO2022241171A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024044486A1 (en) * | 2022-08-22 | 2024-02-29 | Ajax Therapeutics, Inc. | Jak2 inhibitor compounds |
| WO2024102683A1 (en) * | 2022-11-08 | 2024-05-16 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| ES2970229T3 (es) | 2017-03-30 | 2024-05-27 | Bristol Myers Squibb Co | Proceso para la preparación de 6-(ciclopropanamido)-4-((2-metoxi-3-(1-metil-1H-1,2,4-triazol-3-il)fenil)amino)-N-(metil-d3)piridazina-3-carboxamida |
-
2022
- 2022-05-13 IL IL308421A patent/IL308421A/en unknown
- 2022-05-13 EP EP22727672.2A patent/EP4337655A1/en active Pending
- 2022-05-13 US US17/743,557 patent/US11866414B2/en active Active
- 2022-05-13 TW TW111118122A patent/TW202311247A/zh unknown
- 2022-05-13 KR KR1020237042720A patent/KR20240008336A/ko unknown
- 2022-05-13 BR BR112023023425A patent/BR112023023425A2/pt unknown
- 2022-05-13 CA CA3217332A patent/CA3217332A1/en active Pending
- 2022-05-13 AU AU2022271794A patent/AU2022271794A1/en active Pending
- 2022-05-13 JP JP2023570165A patent/JP2024518554A/ja active Pending
- 2022-05-13 WO PCT/US2022/029102 patent/WO2022241171A1/en active Application Filing
-
2023
- 2023-11-07 CL CL2023003308A patent/CL2023003308A1/es unknown
- 2023-11-09 CO CONC2023/0015226A patent/CO2023015226A2/es unknown
- 2023-11-30 US US18/524,426 patent/US20240190829A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220411384A1 (en) | 2022-12-29 |
| JP2024518554A (ja) | 2024-05-01 |
| CA3217332A1 (en) | 2022-11-17 |
| AU2022271794A1 (en) | 2024-01-04 |
| US20240190829A1 (en) | 2024-06-13 |
| US11866414B2 (en) | 2024-01-09 |
| IL308421A (en) | 2024-01-01 |
| CL2023003308A1 (es) | 2024-04-26 |
| EP4337655A1 (en) | 2024-03-20 |
| KR20240008336A (ko) | 2024-01-18 |
| CO2023015226A2 (es) | 2023-11-20 |
| TW202311247A (zh) | 2023-03-16 |
| WO2022241171A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023023425A2 (pt) | Compostos heterocíclicos substituídos | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112021022457A2 (pt) | Inibidores de fgfr e métodos de uso dos mesmos | |
| BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| CL2020001576A1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. | |
| BR112021022778A2 (pt) | Compostos e métodos para o tratamento de covid-19 | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| BR112021002267A8 (pt) | Inibidores de prmt5 | |
| BR112017009647A2 (pt) | 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer | |
| BR112015014590A2 (pt) | composto; composição farmacêutica; estojo ou farmacêutico empacotado; método de inibição de prmt5; método de alteração da expressão de genes; método de alteração da transcrição; e método de tratamento ou prevenção de um distúrbio mediado por prmt5 | |
| BR112012007828B8 (pt) | compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase | |
| BR112021017831A2 (pt) | Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose | |
| BR112023022580A2 (pt) | Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças | |
| BR112023025358A2 (pt) | Inibidores de protease como antivirais | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112021006319A2 (pt) | compostos de indolinona para uso como inibidores de map4k1 | |
| BR112017000132A2 (pt) | composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k | |
| BR112023020781A2 (pt) | Moduladores de cbl-b e usos dos mesmos | |
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| BR112022006572A2 (pt) | Inibidores orais do fator d do complemento | |
| BR112023021161A2 (pt) | Derivados de ureia de piperidina como inibidores de epóxido hidrolase solúveis | |
| BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) |